Aerpio Therapeutics Garners $27,000,000 Series A Funding Round

  • Feed Type
  • Date
  • Company Name
    Aerpio Therapeutics
  • Mailing Address
    9987 Carver Road Cincinnati, OH 45242
  • Company Description
    Aerpio Therapeutics is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    The proceeds will support ongoing development of Aerpio’s pipeline, including AKB-9778, which is entering Phase 1b/2a for the treatment of diabetic macular edema (DME).
  • M&A Terms
  • Venture Investor
    Novartis BioVenture Fund
  • Venture Investor
    Venture Investors
  • Venture Investor
    Triathlon Medical Ventures
  • Venture Investor
    Kearny Venture Partners
  • Venture Investor
    Athenian Venture Partners
  • Venture Investor
    AgeChem Venture Fund